MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.40
+0.22
+1.97%
After Hours: 11.40 0 0.00% 16:00 10/28 EDT
OPEN
11.11
PREV CLOSE
11.18
HIGH
11.46
LOW
10.87
VOLUME
44.04K
TURNOVER
--
52 WEEK HIGH
17.19
52 WEEK LOW
3.000
MARKET CAP
595.65M
P/E (TTM)
-4.1541
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
Autolus' AUTO3 shows promising results in blood cancer study
Autolus Therapeutics (AUTL) announces new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 clinical trial in relapsed/refractory diffuse
Seekingalpha · 09/18 11:00
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
-  AUTO3 shows promise of a highly differentiated product profileConference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BSTLONDON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation
GlobeNewswire · 09/18 07:05
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
Autolus Therapeutics Plc (AUTL) Investor Presentation - Slideshow
The following slide deck was published by Autolus Therapeutics plc in conjunction with this event.
Seekingalpha · 09/11 18:21
Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September
LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO3 data presented at the European
GlobeNewswire · 09/08 11:00
Can You Imagine How Autolus Therapeutics' (NASDAQ:AUTL) Shareholders Feel About The 47% Share Price Increase?
If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...
Simply Wall St. · 09/01 12:48
Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 07:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AUTL. Analyze the recent business situations of AUTOLUS THERAPEUTICS PLC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AUTL stock price target is 27.44 with a high estimate of 50.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 15.88M
% Owned: 30.40%
Shares Outstanding: 52.25M
TypeInstitutionsShares
Increased
13
791.96K
New
16
-773.51K
Decreased
20
1.67M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AUTL
Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Autolus Therapeutics PLC stock information, including NASDAQ:AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.